Please wait...
About This Project
OncoSynergy, Inc.
The Ebola outbreak in west Africa has been declared a global emergency by the WHO with over 1,000 victims and no approved therapies. OncoSynergy is developing a readily manufactured experimental cancer drug, OS2966, which coincidentally targets the receptor hijacked by ebola to infect cells. This project aims to demonstrate that OS2966 inhibits ebola infection of human cells thus providing the impetus for expediting OS2966 for treatment of ebola.
Recent Lab Notes From This Project
Browse Other Projects on Experiment
Related Projects
Saving the most endangered seabird in the Americas
Seven years of intense field monitoring and automated recordings, showed us which factors negatively impact...
What environmental factors control lichen form throughout the redwood canopy?
High up in California's coast redwoods, lichens vary in reproductive form throughout the canopy. The species...
